Business Description
Revolution Medicines is a clinical-stage biotech company focused on developing targeted treatments for cancers driven by RAS gene mutations, a notoriously difficult area of cancer biology. The company has built a pipeline of drug candidates designed to directly block harmful RAS variants, either on their own or alongside other agents that cut off the supporting pathways these cancers rely on. Several of its lead drugs, including daraxonrasib, elironrasib, and zoldonrasib, are currently being tested in clinical trials, with one late-stage study evaluating a combination approach in patients with pancreatic cancer. Founded in 2014 and based in Redwood City, California, the company continues to expand its research into additional RAS mutation types.
